(30 cc heparinized) should be sent to Room AC 125 prior to starting ganciclovir and 
on days 2, 4, 7 and 10 of therapy. 
Clinical Evaluation 
A. Pre-entry Evaluations 
1. HIV-1 antibody by Elisa and Western Blot 
2. HIV-1 Peripheral Blood Mononuclear Cell (PBMC) culture; CSF culture; viral 
isolates will be saved for sensitivity screening 
3. HIV-1 p24 antigen serum and CSF assay 
4. HIV-1 RNA Polymerase Chain Reaction (PCR) gene amplification probe on PBMCs 
and bone marrow aspirate 
5. HIV-1 antibody on donor serum. HIV-1 culture, and PCR assay on donor PBMCs 
6. Storage of recipient and donor PBMCs (Minimum of 5 x 10 6 cells) and serum at -20° 
C to be used for Restriction Fragment Length Polymorphism (RFLP) 
7. T cell profile ratio (OKT4/OKT8) 
8. Immunologic Profile: Serum immunoglobulin electrophoresis; serum B 2 
microglobulin. 
9. Routine CBC; electrolytes panel; PT; PTT; SGOT; SGPT; alkaline phosphatase; 
Coombs; Platelet associated IgG; lumbar puncture to assess CSF protein, CSF 
glucose, CSF cell count, CSF VDRL and CSF culture for bacteria, mycobacteria and 
fungus; routine urinalysis 
10. MRI of cranium 
B. Entry Evaluations 
1. Prior to administration of the first dose of zidovudine, a history and general exam will 
be completed and recorded. 
2. Results of pregnancy tests (for female patients of childbearing potential) will be 
available and recorded. 
3. Results of CBC (with differential, platelet count and MCV, chemistry panel (including 
serum creatinine, BUN, bilirubin (total), SGPT, SGOT, alkaline phosphatase, LDH, 
CPK, and amylase), VDRL and routine urinalysis will be recorded. 
4. Lumbar puncture to assess CSF protein, glucose, cell count, VDRL and CSF culture 
for bacteria, mycobacteria, fungi and viruses including HIV-1. 
5. Subjective symptoms and signs of HIV disease will be assessed and vital signs will be 
recorded. 
6. Any other treatments/medications/biologicals/blood products the patient is receiving at 
the time of enrollment, or has received four weeks prior to enrollment and during 
therapy will be recorded on data collection forms. 
7. Neurological consultation 
8. Zidovudine serum peak and trough level on day -10 
9. Zidovudine CSF peak level on day -10 
10. HIV-1 culture on PBMCs on day -10; viral isolates will be saved for sensitivity 
screening 
11. HIV-1 p24 antigen level on serum and CSF on day -10 
12. HIV-1 PCR RNA on PBMCs on day -10 
13. Western Blot on day -10 
C. Treatment (In-patient) Evaluations 
Recombinant DNA Research, Volume 15 
[627] 
